According to a new market report published by Transparency Market Research “Inhalation and Nasal Spray Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” the global inhalation and nasal spray generic drugs market was valued at US$21.8 bn in 2014 and is estimated to reach US$35.5 bn by 2023 at a CAGR of 5.5% from 2015 to 2023.
Inhalation and nasal spray generic drugs are not associated with any exclusive manufacturer or a brand name and are subject to regulation in countries where they are dispensed. The global inhalation and nasal spray generic drugs market is growing moderately due to increasing incidence respiratory disorders leading to asthma, COPD and other fatal diseases. Moreover, increasing advancements related to generic medication, growing medical awareness, and strong government support would propel the demand for inhalation and nasal spray generic drugs in the coming few years.
The inhalation and nasal spray generic drugs are categorized on the basis of drug class: corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. The combinations segment dominated the global inhalation and nasal spray generic drugs market in 2014. Factors such as greater efficiency and better compliance contributed towards the growth of market segment. The segment is also expected to register the fastest growth during the forecast period. The combinations segment was followed by corticosteroids, in terms of market revenue, in 2014 due to greater healing effect by continuously reducing inflammation caused in the airway owing to asthma.
Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1922
Based on application, the inhalation and nasal spray generic drugs market has been segmented into four types: asthma, COPD, allergic rhinitis, and others which include cystic fibrosis, influenza, etc. Asthma held the largest market share in 2014 and the segment is also projected to grow at the fastest growth rate within the application segment. The major factors driving the growth of the asthma segment during the forecast period from 2015 to 2023 are increasing respiratory infections due to environmental pollution, and growing use of tobacco among the global population.
The global inhalation and nasal spray generic drugs market exhibits intense competition among the existing players. The market is fragmented, characterized by the presence of both established as well as emerging companies. Major players operating in the inhalation and nasal spray generic drugs market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Nephron Pharmaceuticals Corporation, Ranbaxy Laboratories Ltd., Cipla Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals and others.
No comments:
Post a Comment